Pay-for-delay may get Supreme treatment; Pfizer may be raising $1 billion;

@FiercePharma: GSK loses class-action ruling on Paxil in Canada. News | Follow @FiercePharma

> The Supreme Court may decide today whether to jump into the pay-for-delay agreement that the FTC believes is anticompetitive and branded drugmakers think is just good business. Story

> AstraZeneca ($AZN) has selected Par Pharmaceutical to make the authorized copy of its high blood pressure drug Atacand HCT. Item

> Dr. Reddy's Laboratories will import and sell Debiopharm Group's prostate cancer drug Pamorelin in India through an exclusive marketing deal with the Switzerland-based company. Item

> Reuters reports Pfizer ($PFE) is trying to raise $1 billion, with a 5-year revolving line to back its spinoff of its animal health division. Story

> The FDA has granted orphan drug designation to a drug from Biodel to treat congenital hyperinsulinism, a rare disorder that affects children. Release

> The GAVI Alliance says that early next year it will roll out the vaccine against the human papillomavirus in a number of developing countries, including in sub-Saharan Africa, to prove they have the infrastructure to vaccinate girls nationwide. Release

Medical Device News

 @FierceMedDev: NanoString Cancer Dx passes second large-scale test. Article | Follow @FierceMedDev

@MarkHFierce: A $3M Series B round goes to Wright Therapy, which makes lymphedema compression products. Safe, steady investment. Release | Follow @MarkHFierce

 @DamianFierce: Get used to this headline: Startup raises money for renal denervation device. More | Follow @DamianFierce

> Wright Therapy raises $3M Series B for home-use pneumatic compression devices. Item

> FDA wants PMA, not 510(k), for Abiomed's Impella. News

> Cardiosonic seeks $16.1M for renal denervation tech. Story

Biotech News

 @FierceBiotech: Breast cancer vaccine developer bags Teva Pharma, Dx deals to bolster PhIII program. Story | Follow @FierceBiotech

@JohnCFierce: Scientists want more work on apoE as Alzheimer's target (amyloid/tau top suspects) Helps illustrate all the confusion. More | Follow @JohnCFierce

 @RyanMFierce: This Pfizer robbery gives new meaning to a favorite phrase of mine: Pharma gold. Report | Follow @RyanMFierce

> BioCryst Pharma chops half of staff to cap tumultuous two months. Article

> Ecstasy ingredient green-lighted for controversial PTSD study. Report

> Billionaires bankroll R&D institute for Merck KGaA's doomed Geneva facility. News

And Finally... Tom Laughren, director of the Division of Psychiatry Products in the Office of New Drugs in FDA's CDER, has retired after several decades at the agency. Story
 

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.